Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal: Margaret L. MacMillan, MD1, Shernan G. Holtan, MD2, Armin Rashidi, MD, PhD2 et al. ASH oral abstract Dec-2018

Introduction Validation of Minnesota acute GVHD Risk Score Cohort (2008-2016) of 355 patients at University of Minnesota Acute GVHD Treated with prednisone 60 mg/m2/d for 14 days, followed by an 8-week taper Median age 49 years(range <1-75)

Clinical characteristics of patients

Results

Conclusions Minnesota GVHD Risk Score is a valuable To define risk in patients with acute GVHD Predicts outcomes better than GVHD clinical grades Demonstrate the importance of age, HCT-CI, graft source, and time to onset of GVHD on outcomes after GVHD therapy Notably, UCB recipients have better responses to steroid therapy and lower subsequent risk for chronic GVHD than other donor sources. Further studies are needed to explore why cord blood recipients with acute GVHD respond better than BM/PBSC recipients with a similar severity of GVHD.